Home › Companies › Immunovant, Inc. › 2025-2026

Immunovant, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Immunovant, Inc.’s Form 8-K, filed 2025-08-28 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
185Asset managers
1,076Fund votes
2025-08-27Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Immunovant, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Immunovant, Inc.

These tallies are Immunovant, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-08-28 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Immunovant, Inc. — official shareholder meeting results, meeting held 2025-08-27
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Jacob Bauer	152,051,231	--	--	8,193,169	5,641,080	Majority: yes
Elect Director: Douglas Hughes	143,417,281	--	--	16,827,119	5,641,080	Majority: yes
Elect Director: Robert Susman	159,234,780	--	--	1,009,620	5,641,080	Majority: yes
Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the fi	165,422,634	7,237	455,609	--	--	Majority: yes

Source: Immunovant, Inc., Form 8-K, filed with the SEC on 2025-08-28 — read the filing on EDGAR.

How asset managers voted at the Immunovant, Inc. 2025-2026 meeting

Each item below shows how the 185 asset managers that disclosed a Immunovant, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Immunovant, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

99.7% fund support · no official result

FOR 99.6%

The 181 asset managers below cast 99.7% of the shares they voted on this item FOR (78,513,867 for, 205,715 against).

FOR: 78,513,867 (99.6%)AGAINST: 205,715 (0.3%)ABSTAIN: 71,471 (0.1%)NOT VOTED: 109 (0.0%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.” at Immunovant, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	27,653,216	0	For
T. Rowe Price	11,678,394	0	For
Deep Track Capital, LP	9,500,000	0	For
Vanguard	5,743,464	4	For
BlackRock	3,947,998	926	For
Point72	3,375,597	0	For
ARMISTICE CAPITAL, LLC	3,303,973	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,811,967	0	For
State Street	1,484,221	725	For
Charles Schwab	1,307,643	0	For
PICTET ASSET MANAGEMENT SA	1,063,119	0	For
Aberdeen	844,705	0	For
Morgan Stanley	664,831	0	For
Two Seas Capital LP	543,974	0	For
GREAT POINT PARTNERS LLC	524,352	0	For
CANADA PENSION PLAN INVESTMENT BOARD	414,800	0	For
ADAR1 Capital Management, LLC	337,473	0	For
Goldman Sachs	314,422	0	For
Northern Trust	307,120	0	For
Logos Global Management LP	275,000	0	For
Rock Springs Capital Management LP	221,962	0	For
PLATINUM INVESTMENT MANAGEMENT LTD	195,727	0	For
DAFNA Capital Management LLC	191,493	0	For
HighVista Strategies LLC	182,808	0	For
Nuveen	175,987	0	For

Showing the 25 largest of 181 asset managers. See all 181 in the interactive database.

2. To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Jacob Bauer

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 152,051,231WITHHELD: 8,193,169

Immunovant, Inc.’s own tally for this item (“Elect Director: Jacob Bauer”): 152,051,231 for, 8,193,169 withheld, per its Form 8-K filed 2025-08-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 171,069,176 outstanding shares: 89% for, 5% withheld (94% of the company cast a for/withheld vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (21,243,388 for, 0 against).

FOR 81%ABSTAIN 19%

FOR: 21,243,388 (81.4%)ABSTAIN: 4,848,571 (18.6%)NOT VOTED: 54 (0.0%)

Largest asset managers voting on “To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our” at Immunovant, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	11,160,985	0	For
Vanguard	5,609,772	600	For
T. Rowe Price	0	4,619,213	Abstain
BlackRock	2,257,621	0	For
Charles Schwab	646,293	0	For
State Street	531,050	0	For
Morgan Stanley	170,821	0	For
Delaware/Macquarie	0	122,100	Abstain
Equitable	116,028	0	For
Goldman Sachs	111,883	0	For
QUANTITATIVE MASTER SERIES LLC	97,927	0	For
Nuveen	72,220	0	For
Lincoln Financial	52,500	3,450	For
Dimensional	0	50,221	Abstain
Northwestern Mutual	0	48,710	Abstain
ProShares	42,829	0	For
Global X	37,440	0	For
Bridge Builder Trust	35,423	0	For
Victory Capital	31,999	0	For
Guggenheim	29,490	0	For
Direxion Shares ETF Trust	25,937	0	For
TIAA	24,351	0	For
Columbia Threadneedle	21,797	0	For
Pacific Life	20,561	0	For
Brighthouse	17,739	0	For

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

3. To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Douglas Hughes

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 143,417,281WITHHELD: 16,827,119

Immunovant, Inc.’s own tally for this item (“Elect Director: Douglas Hughes”): 143,417,281 for, 16,827,119 withheld, per its Form 8-K filed 2025-08-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 171,069,176 outstanding shares: 84% for, 10% withheld (94% of the company cast a for/withheld vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (20,706,836 for, 0 against).

FOR 79%ABSTAIN 21%

FOR: 20,706,836 (79.4%)ABSTAIN: 5,385,124 (20.6%)NOT VOTED: 54 (0.0%)

Largest asset managers voting on “To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our” at Immunovant, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	9,529,660	1,631,325	For
Vanguard	5,610,373	0	For
T. Rowe Price	4,608,896	10,317	For
BlackRock	0	2,257,621	Abstain
Charles Schwab	646,293	0	For
State Street	1,640	529,410	Abstain
Morgan Stanley	170,821	0	For
Delaware/Macquarie	0	122,100	Abstain
Equitable	13,703	102,325	Abstain
Goldman Sachs	0	111,883	Abstain
QUANTITATIVE MASTER SERIES LLC	0	97,927	Abstain
Nuveen	0	72,220	Abstain
Lincoln Financial	0	55,950	Abstain
Dimensional	0	50,221	Abstain
Northwestern Mutual	48,710	0	For
ProShares	0	42,829	Abstain
Global X	37,440	0	For
Bridge Builder Trust	0	35,423	Abstain
Victory Capital	0	31,999	Abstain
Guggenheim	0	29,490	Abstain
Direxion Shares ETF Trust	0	25,937	Abstain
TIAA	0	24,351	Abstain
Columbia Threadneedle	0	21,797	Abstain
Pacific Life	0	20,561	Abstain
Brighthouse	0	17,739	Abstain

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

4. To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Robert Susman

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%

FOR: 159,234,780WITHHELD: 1,009,620

Immunovant, Inc.’s own tally for this item (“Elect Director: Robert Susman”): 159,234,780 for, 1,009,620 withheld, per its Form 8-K filed 2025-08-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 171,069,176 outstanding shares: 93% for, 0.6% withheld (94% of the company cast a for/withheld vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (26,091,959 for, 0 against).

FOR 99.9%

FOR: 26,091,959 (100.0%)NOT VOTED: 54 (0.0%)

Largest asset managers voting on “To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our” at Immunovant, Inc., 2025-2026
Asset manager	For	Vote
Fidelity	11,160,985	For
Vanguard	5,610,373	For
T. Rowe Price	4,619,213	For
BlackRock	2,257,621	For
Charles Schwab	646,293	For
State Street	531,050	For
Morgan Stanley	170,821	For
Delaware/Macquarie	122,100	For
Equitable	116,028	For
Goldman Sachs	111,883	For
QUANTITATIVE MASTER SERIES LLC	97,927	For
Nuveen	72,220	For
Lincoln Financial	55,950	For
Dimensional	50,221	For
Northwestern Mutual	48,710	For
ProShares	42,829	For
Global X	37,440	For
Bridge Builder Trust	35,423	For
Victory Capital	31,999	For
Guggenheim	29,490	For
Direxion Shares ETF Trust	25,937	For
TIAA	24,351	For
Columbia Threadneedle	21,797	For
Pacific Life	20,561	For
Brighthouse	17,739	For

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

5. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 165,422,634AGAINST: 7,237

Immunovant, Inc.’s own tally for this item (“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent regi”): 165,422,634 for, 7,237 against, per its Form 8-K filed 2025-08-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 171,069,176 outstanding shares: 97% for, 0.1% against (97% of the company cast a for/against vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (26,091,959 for, 0 against).

FOR 99.9%

FOR: 26,091,959 (100.0%)NOT VOTED: 54 (0.0%)

Largest asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independe” at Immunovant, Inc., 2025-2026
Asset manager	For	Vote
Fidelity	11,160,985	For
Vanguard	5,610,373	For
T. Rowe Price	4,619,213	For
BlackRock	2,257,621	For
Charles Schwab	646,293	For
State Street	531,050	For
Morgan Stanley	170,821	For
Delaware/Macquarie	122,100	For
Equitable	116,028	For
Goldman Sachs	111,883	For
QUANTITATIVE MASTER SERIES LLC	97,927	For
Nuveen	72,220	For
Lincoln Financial	55,950	For
Dimensional	50,221	For
Northwestern Mutual	48,710	For
ProShares	42,829	For
Global X	37,440	For
Bridge Builder Trust	35,423	For
Victory Capital	31,999	For
Guggenheim	29,490	For
Direxion Shares ETF Trust	25,937	For
TIAA	24,351	For
Columbia Threadneedle	21,797	For
Pacific Life	20,561	For
Brighthouse	17,739	For

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (95,011 for, 0 against).

FOR: 95,011 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Immunovant, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Granahan Investment Management, LLC	94,123	0	0	0	For
JPMorgan	888	0	0	0	For

Largest Immunovant, Inc. shareholders voting in 2025-2026

Ranked by the number of Immunovant, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 171,069,176 shares outstanding at the time of that meeting.

Top Immunovant, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	16.16%
2	T. Rowe Price	6.83%
3	Deep Track Capital, LP	5.55%
4	Vanguard	3.36%
5	BlackRock	2.31%
6	Point72	1.97%
7	ARMISTICE CAPITAL, LLC	1.93%
8	GEODE CAPITAL MANAGEMENT, LLC	1.06%
9	State Street	0.87%
10	Charles Schwab	0.76%

Reported Immunovant, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Immunovant, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Roivant Sciences Ltd.	66.25%	DEF14A
FMR (Fidelity)	9.91%	13F
FMR LLC	8.61%	DEF14A
Vanguard Group	4.55%	13F
BlackRock	3.84%	13F
Morgan Stanley	2.83%	13F
State Street	2.65%	13F
Geode Capital	1.22%	13F
Frank M. Torti	1.14%	DEF14A
Goldman Sachs	1.04%	13F

Percentages above are of 171,069,176 shares outstanding, as reported by Immunovant, Inc. on its Form 10-Q dated 2025-06-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Immunovant, Inc.’s 10-Q dated 2025-06-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Immunovant, Inc.'s shareholder meeting held 2025-08-27, in the 2025-2026 proxy season, 185 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,076 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Immunovant, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — the reporting funds cast 99.7% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Immunovant, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).